A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations
Clinical trial NCT01310036 · COMPLETED
Trial details
- NCT number
- NCT01310036
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-04-30
- Primary completion
- 2014-02-14
- Enrollment
- 208
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.